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ABSTRACT 
G-protein coupled receptors (GPCR)-mediated signalling is a more complicated 
process than described previously since every GPCR and GPCR heteromer requires a 
set of G protein interacting proteins (GIP) which interacts with the receptor in an 
orchestrated spatio-temporal fashion. Therefore, there is a high interest in 
understanding the dynamics of the receptor-receptor and receptor-protein interactions 
in space and time, and specially, their integration in GPCR heterocomplexes of the 
Central Nervous System (CNS). Also, pathological protein-protein interactions in 
homocomplexes and heterocomplexes of Aβ, Tau, and α-Syn are at the heart of the 
development of conformational protein disorders. Along this work, experimental 
evidences are given to illustrate that GPCR interactions have relevance for 
neurological and mental diseases and are targets for drug development. GPCR 
containing heteromers and higher order heteromers through allosteric receptor-
receptor interactions have become major integrative centers at the molecular level and 
their receptor protomers act as moonlighting proteins. They have become exciting 
new targets for neurotherapeutics in e.g. Parkinson’s disease, schizophrenia, drug 
addiction, anxiety and depression opening up a new field in 
neuropsychopharmacology. 
Along this work, the allosteric receptor-receptor interactions over the interfaces in 
A2AR-D2R, D2R-NTS1R, D2R-Sigma1R and 5-HT1A-FGFR1 heteroreceptor 
complexes will be explored and their biochemical, pharmacological and functional 
integrative implications in the CNS described. Methodologies for studies on receptor-
receptor interactions are discussed including the use of FRET and BRET-based 
techniques in the analysis of G protein coupled receptor (GPCR) dimerization in 
living cells. In situ proximity ligation assay is performed to establish the existence of 
native heteroreceptor complexes in the CNS. GPCR interacting proteins (specially β-
arrestin) and their receptor-protein interactions are also covered but their interactions 
with the allosteric receptor-receptor interactions in heteroreceptor complexes remain 
to be elucidated. The physiological and pathological relevance of the allosteric 
receptor-receptor interactions in heteroreceptor complexes is emphasized and novel 
strategies for treatment of mental and neurological disease are introduced based on 
this new biological principle of integration.  
This work gives further experimental evidences which strongly support the current 
view that allosteric receptor–receptor interactions in heteroreceptor complexes appear 
to represent a new principle in biology making possible integration of signals already 
at the level of the plasma membrane. These heteroreceptor complexes and their 
dynamics may be part of the molecular basis of learning and memory. The receptor 
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protomers and their allosteric receptor-receptor interactions can be disturbed in 
neurological and mental disorders, and in diseases of peripheral tissues like the 
endocrine, cardiovascular and immune systems.  
The dopamine (DA) neuron system most relevant for schizophrenia and Parkinson´s 
diseases is the meso-limbic-cortical DA system inter alia densely innervating subcortical 
limbic regions as well as the dorsal striatum. The field of dopamine D2Rs changed 
significantly with the discovery of many types of D2R heteroreceptor complexes in the 
ventral and dorsal striatum. The results indicate that the D2R is a hub receptor 
(www.gpcr-hetnet.com) which interacts not only with many other GPCRs including DA 
isoreceptors but also with ion-channel receptors, receptor tyrosine kinases, scaffolding 
proteins and DA transporters. Disturbances in several of these D2R heteroreceptor 
complexes may contribute to the development of schizophrenia and Parkinson´s diseases 
through changes in the balance of diverse D2R homo- and heteroreceptor complexes 
mediating the DA signal, especially to the ventral striato-pallidal GABA pathway. In 
schizophrenia, this will have consequences for the control of this pathway of the 
glutamate drive to the prefrontal cortex via the mediodorsal thalamic nucleus which can 
contribute to psychotic processes.  
Allosteric receptor-receptor interactions in GPCR heteromers appeared to introduce an 
intermolecular allosteric mechanism contributing to the diversity and bias in the GPCR 
protomers. In A2A-D2R heteroreceptor complexes allosteric A2A-D2R receptor-
receptor interaction brings about a biased modulation of the D2R protomer signalling 
(Chapter 1). A conformational state of the D2R is induced which moves away from Gi/o 
signaling and instead favours b-arrestin2 mediated signalling which may be the main 
mechanism for its atypical antipsychotic properties especially linked to the limbic 
A2AR-D2R heteroreceptor complexes. Furthermore, D2R-NTS1R heterocomplexes also 
exist in the ventral and dorsal striatum (Chapter 2) and likely also in midbrain DA nerve 
cells as D2R-NTS1R autoreceptor complexes where neurotensin produces antipsychotic 
and propsychotic actions, respectively. D2R protomer appeared to bias the specificity of 
the NT orthosteric binding site towards neuromedin N vs neurotensin in the 
heteroreceptor complex.  
There is a new awareness that Receptor tyrosine kinases (RTK) and transmitter activated 
GPCR possess the capacity for transactivation not only via GPCR induced release of 
neurotrophic factors, but also during signal initiation and propagation, using shared 
signaling pathways or using themselves as signaling platforms via direct allosteric 
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receptor–receptor interactions. RTK are a family of transmembrane-spanning receptors 
that mediate the signaling from ligands such as growth factors, like the platelet-derived 
growth factor (PDGF), epidermal growth factor (EGF), the brain derived neurotrophic 
factor (BDNF), and the fibroblast growth factor (FGF). This hypothesis on direct GPCR-
RTK receptor-receptor interactions in heteroreceptor complexes was introduced by Fuxe 
et al 1983. They also proposed the existence of 5-HT1A-FGFR1 heteroreceptor 
complexes having a role in depression. The hypothesis was introduced that the 
neurotrophic system FGF-2/FGFR1 may be a good candidate to mediate antidepressant 
induced improvement in 5-HT neuronal communication and neurotrophism with 
regeneration of connections lost during depression. RTK transactivation in response to 
antidepressant drug treatment was postulated to take place via a new allosteric receptor–
receptor between distinct serotonin receptor subtypes and FGFR1 in heteroreceptor 
complexes. 
The discovery of brain FGFR1-5-HT1A heteroreceptor complexes and their 
enhancement of neuroplasticity offers an integration of the serotonin and the 
neurotrophic factor hypotheses of depression at the molecular level. These 
heteroreceptor complexes were found in the hippocampus and midbrain raphe 5-HT 
nerve cells, enriched in 5-HT1A autoreceptors. Based on the triplet puzzle theory several 
sets of triplet homologies were identified that may be part of the receptor interface. 
Combined FGF-2 and 5-HT1A agonist treatment increased the formation of these 
heterocomplexes and the facilitatory allosteric receptor-receptor interactions within them 
leading to an enhancement of FGFR1 signaling (Chapter 3). This integrative 
phenomenon is reciprocal and RTK signaling can be placed downstream of GPCRs. 
Formation of such heterocomplexes involving two major classes of membrane receptors 
can be involved in regulating all aspects of receptor protomer function including 
recognition, signaling, trafficking, desensitization, and downregulation (Chapter 3). 
These events were associated with development of rapid antidepressant effects. These 
heteroreceptor complexes are a novel target for antidepressant drugs. 
These examples, based on solid experimental evidences, serve to illustrate that allosteric 
receptor-receptor interactions in GPCR heteroreceptor complexes play a significant role 
in receptor diversity and bias of the participating GPCR protomers. 
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RESUMEN EN ESPAÑOL 
Los mecanismos de señalización mediados por los receptores acoplados a la proteína 
G (GPCR) son procesos muchos más complejos e interconectados que los descritos 
hasta el presente. Habida cuenta que cada receptor o complejo de receptores requiere 
un conjunto de interacciones proteicas que faciliten de forma orquestada, en tiempo y 
espacio, la transmisión de la señal. Por tanto, es de sumo interés comprender y 
estudiar la dinámica de estos procesos de interacción entre los receptores de 
membrana y las proteínas intracelulares que interactúan con los mismos, tanto en el 
tiempo como en el espacio, para poder tener una compresión global de los 
mecanismos de integración de la señal en el Sistema Nervioso Central (SNC) y su 
implicación en el desarrollo de las enfermedades mentales y neurodegenerativas. Por 
ejemplo, se sabe que ciertas interacciones disfuncionales entre proteínas, los péptidos 
Aβ, Tau, y α-Syn, son consideradas el centro de los mecanismos moleculares de 
muchas enfermedades neurodegenerativas. También, a lo largo del presente trabajo, y 
basado evidencias experimentales, se ilustra la importancia de diversos complejos 
heteroreceptores de la familia de los GPCR como futuras dianas o blancos para el 
tratamiento de enfermedades neurodegenerativas (A2AR-D2R, enfermedad del 
Parkinson) y mentales (5-HT1A-FGFR1, depresión).   
Los complejos de homo y heteroreceptores a través de sus interacciones alostéricas 
entre los diversos componentes del complejo se han convertido en centros de 
integración molecular muy sofisticados a nivel molecular que facilitan el desarrollo 
de capacidades multifuncionales de sus protómeros. Estos se convierten así, en si 
mismos, en excelente dianas o blancos para el desarrollo de nuevos neurofármacos o 
líneas neuroterapéuticas en enfermedades tales como el Parkinson, la esquizofrenia, la 
adición a drogas, la ansiedad y la depresión.  
En la presente tesis, las interacciones alostéricas entre los receptores componentes de 
los homo y heterocomplejos de los receptores A2AR-D2R, D2R-NTS1R, D2R-
Sigma1R y 5-HT1A-FGFR1 son exploradas y evidenciadas mediante el uso métodos 
bioquímicos, de biología molecular y neurofarmacología. Los métodos para el estudio 
de las interacciones receptores-receptores en modelos celulares utilizados en el 
presente estudio incluyen las modernas técnicas biofísicas de FRET y BRET. Así 
mismo para el estudio y comprensión de las interacciones en tejidos animales, ex 
vivo, se han empleado y optimizado los ensayos in situ de ligación por proximidad (in 
situ PLA). El papel relevante de las interacciones entre los complejos 
heteroreceptores y la β-arrestina son también descritos y estudiados mediante ensayos 
de microscopía confocal y BRET. Sin embargo, su incidencia en los mecanismos 
alostéricos que se producen a través de las interacciones receptor-receptor en los 
heterocomplejos permanecen aún sin descifrar.  
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Las nuevas evidencias experimentales expuestas enfatizan y confirman la relevancia 
fisiológica y patofisiológica de las modulaciones alostéricas que operan a través de 
las interacciones receptor-receptor en los homo y heterocomplejos. Así como la 
necesidad de hacer énfasis en el desarrollo de nuevas moléculas o fármacos, que 
consideren esta nueva realidad molecular o principio biológico de integración de la 
señal, para el desarrollo de tratamientos farmacológicos más eficaces en el 
tratamiento de enfermedades mentales y neurodegenerativas.  
Se aportan además, nuevas evidencias que apoyan de manera contundente el estado 
actual de los conocimientos en el campo de la integración molecular a nivel sináptico 
mediante la formación de homo y heterocomplejos dinámicos y sus respectivas 
modulaciones alostéricas a través de la interfase de interacciones de sus 
correspondientes protómeros. Estos complejos de heteroreceptores pueden 
considerarse parte de las bases moleculares de los mecanismos de aprendizaje y 
memoria a nivel neuronal. Alteraciones o cambios en su composición, el balance o 
equilibrio entre las diferentes poblaciones de homo- y heteroreceptores o sus 
mecanismos alostéricos por variaciones en su interfase de interacción; pueden 
representar las bases moleculares de muchas enfermedades neurológicas o 
neurodegenerativas en el SNC.  
Se ha tomado como modelo de estudio el sistema dopaminérgico, que a través de su 
densa innervación, cortical-meso-límbico, de las regiones límbicos subcorticales y el 
estriado dorsal, está asociado fundamentalmente a dos patologías neuronales: la 
esquizofrenia y el Parkinson. A partir de esto y el hecho de la elevada complejidad a 
nivel molecular de las membranas sinápticas, donde un alto número de complejos 
homo y heteroreceptores para los receptores de la dopamina han sido recientemente 
descritos y estudiados (www.gpcr-hetnet.com), se hizo imprescindible considerar que 
perturbaciones en algunos de estos homo y heterocomplejos pueden estar en la base 
de los mecanismos moleculares de estas enfermedades del SNC. Se sabe que el 
receptor de la dopamina tipo D2R puede ser considerados como un receptor "hubs", 
que se caracteriza por una gran plasticidad para la interacciones con diversos tipos de 
receptores, no solo dentro de la propia familia de los GPCR, sino también con otras 
proteínas y receptores de membranas como los canales iónicos, los transportadores, 
proteínas RAMPS, etc. Cambios en los balances de diversos homo y heterocomplejos 
del receptores de la dopamina D2R, especialmente en la vía estriado-palidal-
gabaérgica, pueden acarrear cambios no solo en los mecanismos de transmisión de la 
señal sino también en el control de los impulsos glutamatérgicos.  
Las modulaciones alostéricas que operan a través de interacciones receptor-receptor 
introducen un nuevo mecanismo intermolecular que facilitan y contribuyen al 
desarrollo de procesos de diversificación y especificidad de la señal de los respectivos 
protómeros. En los complejos de heteroreceptores para la adenosina A2AR- y la 
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dopamina D2R (A2AR-D2R), las modulaciones alostéricas que operan y tienen lugar 
entre la interacción del receptor A2AR y D2R resultan en una compensación 
antagónica y un cambio en la selectividad por la señal de cada uno de los respectivos 
protómeros (Capítulo 1). El cambio conformacional inducido en el receptor de la 
dopamina D2R resulta en una perdida por la afinidad a la proteína G i/0 y un 
incremento significativo en la interacción del receptor D2R por la proteína 
citoplasmática β-arrestina, cambio que puede estar en la base de las propiedades 
antipsicóticas atípicas relacionadas con el receptor D2R. Estas modulaciones 
alostéricas operan a través de una interfase de interacción receptor-receptor muy bien 
definida y caracterizada, en la que solo ciertos amino ácidos actúan como puntos 
calientes o de encuentros, en lugar de amplios segmentos de la secuencia 
polipeptídica (Capítulo 1). En línea con estos resultados, también se ha demostrado la 
existencia de un complejo heteroreceptor entre el receptor de dopamina D2R y el 
receptor de neurotensina 1 (NTS1R) en el estriado dorsal y ventral del cerebro de rata 
(Capítulo 2). Se ha demostrado que el protómero (D2R) produce un cambio en la 
selectividad y afinidad del sitio ortostérico del receptor NTSR1, resultando en un 
aumento de la interacción y afinidad de la neuromedina N respecto a la neurotensina, 
así como cambios en los patrones de internalización.  
Por otra parte, existe actualmente cierto consenso en las evidencias de que los 
receptores tirosina quinasa (RTK) pueden ser trans-activados vía la liberación por 
factores tróficos a través de la activación de los GPCR, pero también mediante 
mecanismos más directos en los que tienen lugar la formación de complejos de 
interacción en la membrana citoplasmática de estas dos familias de receptores de 
membranas. Los RTK son una familia de receptores transmembrana que operan 
como receptores de señal de factores neurotróficos como son: el factor de 
crecimiento epidérmico (EGF), el factor de crecimiento derivados de plaquetas 
(PDGF), el factor neurotrófico derivado del cerebro (BDNF), y el factor de 
crecimiento de fibroblastos (FGF).  
La hipótesis de una interacción directa en la membrana citoplasmática entre  
receptores RTK y GPCR fue introducida en el año 2007 por el Dr. sueco Kjell Fuxe y 
sus colaboradores. Un año más tarde fue confirmada por el premio Nobel Paul 
Greengard y su equipo de investigación de la Universidad de Rockefeller. El grupo 
de Fuxe también propuso en el año 2007 la existencia de un complejo de 
heteroreceptores (5-HT1A-FGFR1) en el SNC y su posible implicación o relevancia 
en los mecanismos moleculares de las enfermedades depresivas. Se sugirió que el 
sistema neurotrófico FGF-2/FGFR1 puede considerarse como un buen candidato o 
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diana para el desarrollo de nuevos compuestos anti-depresivos si se consideraba 
desde el punto de vista de la interacción de estos receptores (FGFR1) con los 
receptores de serotonina, especialmente los receptores del subtipo 5-HT1A. La 
transactivación de los receptores RTK en respuesta a los tratamientos antidepresivos 
se postuló desde la base de los mecanismos alostéricos de interacción receptor-
receptor que pueden operar entre los receptores FGFR1-5HT1A.  
Cinco años más tarde, en el año 2012, se descubrió la existencia de complejos de 
heteroreceptores entre el FGFR1-5HT1A en el cerebro de las ratas, especialmente en 
el hipocampo, las regiones del rafe medio dorsal y el córtex prefrontal. Se 
demostraron además una serie de mecanismos de señalización celular orquestados 
por la interacción de estos dos receptores, que contribuyen el incremento de la 
plasticidad neuronal y la formación de nuevos botones y dendritas en cultivos 
primarios de células del hipocampo. También, basado en la teoría del rompecabezas 
por triplete de amino ácidos (amino acid triplet puzzle theory) se demostró la 
existencia de una serie de tripletes que conforman la interfase de interacción entre el 
receptor FGFR1 y el 5-HT1A. En el presente trabajo (Capítulo 3) se aportan también 
nuevas evidencias de que la co-estimulación de ambos protómeros en el 
heterocomplejo 5-HT1A-FGFR1 resulta en un significativo incremento de la 
formación de nuevos complejos en la membrana plasmática, así como un aumento en 
los procesos de homodimerización de los respectivos protómeros. Se observó 
además, que el mecanismo alostérico como resultado de las interacciones receptor-
receptor, resultan en un aumento significativo de la unión de ciertas proteínas 
intracelulares a ambos protómeros (por ejemplo, la β-arrestina), así como un aumento 
de la señalización vía las MAPK. Estos mecanismos de integración de la señal son 
recíprocos y las plataformas de señalización para los RTK pueden subordinarse a las 
de los GPCR y viceversa. La formación de los complejos RTK-GPCR son dinámicas 
y muy interrelacionadas, impactando en todos los niveles estructurales y funcionales 
de cada uno de estos receptores, desde el reconocimiento, hasta la señalización, la 
internalización y tráfico (Capítulo 3).  
En resumen, el presente trabajo mediante el estudio de una seria de complejos de 
homo y heteroreceptores en el SNC, aporta las bases experimentales suficientes para 
demostrar e ilustrar que los mecanismos alostéricos mediados por interacciones 
"receptor-receptor" en complejos multiprotéicos desempeñan un importante papel en 
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la integración de la señal y en los mecanismos de selectividad y diversidad de los 
protómeros involucrados. También se abre la puerta al desarrollo de nuevos fármacos 
y terapias en los que se tengan en cuenta estas particularidades. 
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INTRODUCTION 
1.1 History of receptor-receptor interactions 
In the early 1980ies it was observed that neuropeptides can alter the affinity and 
density of the monoamine agonist and antagonist binding sites in different regions of 
the Central Nervous System (CNS), in a receptor subtype specific way 1-4. The 
molecular mechanisms for these intramembrane events between neuropeptide and 
monoamine receptor subtypes were unknown but direct interactions between the two 
receptors were postulated. Thus, it indicated the presence of neuropeptide-
monoamine receptor-receptor interactions in the plasma membrane and the 
introduction of the heteroreceptor complexes hypothesis 2, 5.  
The demonstration of neuropeptide-monoamine receptor–receptor interactions in 
membrane preparations from different regions of the CNS indicated e.g. the existence of 
DA receptor subtype–specific interactions with neurotensin (NT) and cholecystokinin 
(CCK) receptors in putative brain heteroreceptor complexes 3, 6-9. The stronger  allosteric 
NTR-D2R and CCKR-D2R interactions found in sections than in membrane 
preparations indicated the requirement of intracellular mechanisms and/or a more intact 
membrane structure for optimal receptor-receptor interactions 3, 4, 10.  
In line with these results on neuropeptide induced changes in the affinity of the 
monoamine receptor subtypes 11, 12, Lefkowitz, Limbird and colleagues had earlier 
discovered negative cooperativity in beta adrenergic receptors 13, 14. This can be 
explained on the basis of the existence of beta adrenergic homoreceptor complexes 
which leads to site–site interactions. The first symposium on receptor–receptor 
interactions among GPCRs was held in Stockholm in 1986 5. In the preface to the 
symposium book the receptor-receptor interaction field was proposed to become 
wider and include also interactions between different classes of biologically active 
macromolecules such as receptors, ion channels and ion pumps.  
Heteroreceptor complexes was postulated again in 1993 to be the molecular basis for 
the receptor–receptor interaction 15. The first observations indicating the existence of 
homodimerization of GPCR were made in 1982 16, 17. In 1987 homodimerization was 
found to take place upon epidermal growth factor (EGF) induced stimulation of the 
epidermal growth hormone receptor 18. Ten years later the demonstration of the 
GABA B receptor heterodimer (see 19-21) validated Fuxe group early findings 
indicating receptor-receptor interactions in putative GPCR heteroreceptor complexes 
2, 15. Thus, in words of the eminent Swedish neuroscientist Kjell Fuxe, the entire 
decoding process becomes a branched process already at the receptor level in the 
plasma membrane. For a review of the early work on receptor-receptor interactions, 
see 3, 4, 6-8, 22-29.  
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The allosteric receptor-receptor interactions over the interfaces in homo and 
heteroreceptor complexes and their biochemical, pharmacological and functional 
integrative implications in the CNS will be dealt with in this thesis work. The 
resemblance of the receptor protomers to moonlighting proteins will be also 
underlined 27, 30, 31. Heteroreceptor complexes appear to be a fundamental principle 
for molecular integration in biology 23, 28. The involvement of GPCR interacting 
proteins in these heteroreceptor complexes will also be covered 6, 27, 32. We will also 
reveal how the discovery of different types of receptor–receptor interactions in such 
complexes in the brain led to novel strategies for treatment of Parkinson’s disease 
(e.g. A2A and mGluR5 receptor antagonists) 33, schizophrenia (e.g.A2A and mGluR5 
agonists) 4, 34, depression (e.g. 5-HT1A agonists enhancing FGFR1 function) 35 and 
cocaine addiction (e.g.A2A agonists) 36. It contributed to the introduction of A2A 
receptor antagonists in the treatment of Parkinson’s disease 33, 37, 38. 
 
1.2. Heteroreceptor complexes and their allosteric receptor-receptor interactions 
It was proposed that the receptor-receptor interactions in the plasma membrane took 
place in postulated heteroreceptor complexes of GPCRs which could involve the 
participation of adapter proteins; see 3, 7, 9, 27. Now the receptor field in the CNS has 
changed and include not only the monomers but also homo and heteroreceptor 
complexes of unknown stoichiometry and geometry as novel targets for treatment of 
neurological and mental diseases (Figure 1)23, 28.  
 
 
Figure 1. GPCR protomers forming heteroreceptor complexes results in increases in the diversity of 
recognition and signalling. Theses results underline the view of GPCRs as moonlighting proteins. 
Changes in the allosteric receptor-receptor interaction through the formation of different types of 
heteroreceptor complexes and receptor/protein complexes can change the function of an individual 
receptor present as homomer or monomer (This figure and text has been obtained from 27). 
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It is of highly relevant that dopamine D2Rs form higher order homoreceptors at 
physiological expression levels in living cells as was demonstrated using protein 
complementation assays combined with BRET 39. Also, it was observed that 
allosteric receptor-receptor interactions are in operation between protomers of D2R 
homoreceptor complexes which modulate their activation 40. Using a functional 
complementation assay it became possible to evaluate the D2R homoreceptor 
functional unit and directly study their receptor-G protein interactions. The evidence 
suggests an asymmetrical activated D2R homoreceptor complexe where the second 
D2R protomer inhibits signalling. 
The allosteric receptor-receptor interactions in heteroreceptor complexes give 
diversity, specificity and bias to the receptor protomers due to conformational 
changes in discrete domains leading to changes in receptor protomer function and 
their pharmacology 3, 7, 9, 27, 28. The discovery of the adenosine A2AR- dopamine D2R 
heteroreceptor complexes in the dorsal striato-pallidal GABA neurons with 
antagonistic A2AR-D2R interactions reducing D2R signalling led to the development 
of A2AR antagonists for treatment of Parkinson’s disease 7, 27 and A2AR agonist for 
the treatment of cocaine used disorders 36 (Figure 2). The motor complications found 
with levodopa like dyskinesias and wearing off can involve a reorganization of these 
heteroreceptor complexes involving also a disbalance with A2AR and D2R 
homoreceptor complexes 7, 8, 37. 
 
 
Figure 2. Illustration of the antagonistic allosteric receptor-receptor interactions in the A2AR-D2R 
heteroreceptor complexes with several possible stoichiometries from heterodimers to higher order 
heteromers of various types (heterotrimer and heterotetramer are shown) with or without 
the participation of adapter proteins (Ater). These proteins may participate in the mediation of the 
allosteric interaction by e.g., guiding the receptors towards each other through a scaffolding function. 
Such actions may also regulate the time of the heteromerization from being transient to becoming 
more stable and long lasting. The major allosteric interaction appears to be an antagonistic A2AR-D2R 
interaction by which the A2AR protomer inhibits the D2R protomer recognition (reduced affinity) and 
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Gi/o mediated signaling switching it towards a state dominated by beta-arrestin mediated signaling. 
The heterocomplexes are in balance especially with the corresponding A2AR and D2R homoreceptor 
complexes but also with other colocated D2R heterocomplexes and A2AR heterocomplexes in the 
synapses and their extrasynaptic regions in the striato-pallidal GABA neurons. (The text and the figure 
has been obtained from 23) 
 
Neurotrophic and antidepressant effects of 5-HT in brain may, in part, be mediated 
by activation of the 5-HT1A receptor protomer in the hippocampal FGFR1–5-HT1A 
heteroreceptor complex enhancing the FGFR1 signalling 24, 35, 41, 42. The FGFR1-5-
HT1A heteroreceptor complex likely represents a novel target for antidepressant 
drugs and offers a novel strategy for treatment of depression 24.  
FGFR1–5-HT1A heteroreceptor complexes are also found in the majority of the 5-
HT nerve cells in the dorsal and median raphe nuclei 41. 5-HT1A autoreceptors by 
being part of this heteroreceptor complex may have also a trophic role in the 5-HT 
neuron systems. The majority of the ascending midbrain 5-HT neurons may be 
dysregulated in depression and have a reduced trophic support due to disruption or 
dysfunction of these receptor complexes in the 5-HT nerve cells 3, 24.  
Furthermore, a single GPCR through conformational changes due to its participation 
in an altered receptor complex may undergo changes in co-trafficking with increased 
internalization and can become possible transcription factors through their altered 
conformation and possible receptor fragments formed. As possible transcription 
factors the GPCRs would have a novel function by directly modulating gene 
expression and likely trophism, possible actions of relevance for neurodegeneration. 
Allosteric receptor-receptor interactions in GPCR-RTK heteromers likely will lead to 
moonlighting of the participating GPCR and RTK protomers with high relevance for 
neurodegeneration 43-45. 
Taken together, GPCR heteroreceptor complexes and their receptor-receptor 
interactions represent a new fundamental principle in molecular medicine for 
integration of transmitter signals in the plasma membrane. A novel understanding of 
the molecular basis of CNS diseases is given together with new strategies for their 
treatment by targeting heteroreceptor complexes based on a new pharmacology with 
combined treatment, multi-targeted drugs and heterobivalent drugs 23, 28. 
 
1.3  D2R-NTR1 heteroreceptor complexes  
Neurotensin (NT) was found to reduce the affinity of D2R agonist binding sites which 
correlated with its ability to counteract the DA agonist induced inhibition of striatal DA 
and GABA release and to induce neuroleptic actions with relevance for its postulated 
anti-psychotic actions 2, 3, 6. Thus, in the striatum a prejunctional allosteric antagonistic 
D2R-NTR1 autoreceptor interaction in striatal DA terminals increasing DA release and a 
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postjunctional allosteric antagonistic D2R-NTR1 interaction mainly located on the 
cortico-striatal glutamate nerve terminals but also on the striato-pallidal GABA neurons 
increasing their activity and GABA release. 
It was of substantial interest that the C-terminal NT(8-13) fragment also potently and 
antagonistically modulated rat neostriatal D2Rs and that neuromedin N (NN) also was a 
potent inhibitory modulator of D2R agonist binding in rat neostriatal membranes 1, 2, 5. In 
view of the higher potency of NN versus NT to modulate the affinity of neostriatal 
D2Rs, in contrast to the higher potency of NT vs NN to bind to the cloned NTRs, the 
NN-activated neostriatal NT receptors involved in the affinity regulation of the D2Rs, 
may have developed a bias towards NN vs NT in terms of affinity and/or potentially 
efficacy. This may have been accomplished through a reciprocal allosteric D2R-NTR 
interaction from the D2R protomer biasing the specificity of the NT orthosteric binding 
site towards NN vs NT binding in the heteroreceptor complex 3, 7.  
It should be noticed that the antagonistic presynaptic but not the postsynaptic D2R-
NTR1 receptor-receptor interaction was missing in the nucleus accumbens in contrast to 
dorsal striatum. This led to increases in ventral striatal GABA release as in the dorsal 
striatum but without increases in DA release. Instead reductions of accumbens DA 
release were observed likely at least in part related to activation of GABA A receptors on 
the DA terminals. Thus, regional differences in the microanatomy of the NTR-D2R 
heteroreceptor complexes can have important regional functional consequences at the 
local circuit levels of the ventral and dorsal striatum leading to a differential regulation 
of the striato-pallidal GABA outflow from these two regions by NT. The NT induced 
reduction of D2R signaling in the ventral striatum therefore become stronger in the 
ventral striatum vs the dorsal striatum which will favor antipsychotic actions vs 
development of motor side-effects 3, 4, 6, 7. 
 
1.4 Dynamics and bias through antagonistic reciprocal receptor-receptor 
interactions in A2AR-D2R heteroreceptor complexes  
Adenosine A2A receptor (A2AR)–dopamine D2 receptor heteroreceptor complexes was 
demonstrated by means of biochemical and biophysical methods, namely co-
immunoprecipitation, bioluminescence resonance energy transfer (BRET), and 
fluorescence resonance energy transfer analyses, upon transient cotransfection of the two 
receptors in cell lines 46-48. A2AR-D2R heteroreceptor complexes were later on also 
found in the striatum using the PLA technique 49, 50. 
Antagonistic A2AR-D2R receptor-receptor interactions in striatal membrane 
preparations were early on demonstrated after incubation with A2AR agonist CGS21680 
as seen from demonstrated by the reduction of the affinity of the high affinity D2R 
agonist binding site 33. With receptor autoradiograpy strong reductions in affinity were 
observed after A2AR agonist treatment in the nucleus accumbens core and shell of the 
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rat 37. Significant increases in the EC50 values were also observed in the human caudate 
after incubation of the sections with CGS21680. Furthermore, the antagonistic A2AR–
D2R interaction in A2AR–D2R heteroreceptor complexes diminished the Gi/o mediated 
signaling of the D2R 51. In D2R-A2AR cotransfected neuroblastoma cells, coactivation 
of A2AR and D2R resulted in the coaggregation, cointernalization, and codesensitization 
of the A2AR and D2R 52. Recently it was shown that that the activation of the A2AR-
D2R interaction also favors β-arrestin2 recruitment to the D2LR protomer with 
subsequent increase in cointernalization 53. Thus, this allosteric A2AR-D2R receptor-
receptor interaction brings about a biased modulation of the D2 protomer signaling 
(Figure 2). A conformational state of the D2R protomer is induced which moves away 
from Gi/o signaling and instead favours  binding of β-arrestin2 and β-arrestin2 mediated 
signaling 52, 53. This change in functional selectivity can in part explain the reduced time 
onset of Akt phosphorylation after the A2AR-D2R coactivation followed by a rapid 
dephosphorylation 3, 6-9.  
The existence of an electrostatic interaction between the C-terminal tail of the A2AR and  
the third intracellular loop (IL3) of the D2R was demonstrated to be importantly 
involved in the A2AR protomer-mediated allosteric effects on the D2R protomer 
recognition, signaling and trafficking 52. Electrostatic bonds of covalent-like strength are 
formed in this interaction and a detailed mutational analysis was made in the A2AR C-
terminal tail 7, 52 (Figure 3). 
Recently evidence was obtained for the existence of a reciprocal allosteric 
communication from the D2R to the A2AR protomer  of the A2AR-D2R heteromer 51. 
This allosteric receptor–receptor interaction was found to be mostly mediated by two 
regions rich in arginins known to give with positive charges, located in IL3 of the D2R. 
The negative allosteric modulation by the D2R on A2AR agonist binding was shown in a 
real-time mode. It was possible to determine that D2R activation in part inhibited and 
also slowed the binding a of the fluorescent A2AR agonist to the A2AR 3, 51, 54. The  
interaction was abolished by mutating the IL3 of the D2R. The Arg residues (217–222 
and 267–269) in IL3 of the D2R were as demonstrated to play a major role in the 
antagonistic allosteric D2R-A2AR receptor-receptor interaction (Figure 3). This 
allosteric receptor-receptor interactions makes possible also an inhibitory modulation by 
the D2R protomer of the A2AR protomer binding and function. 
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Figure 3. GPCR heteromer receptor interface ilustrated in the A2AR-D2R heteromers . (Helix-helix 
interaction) Representations  are shown from a lateral view of the D2R (TM-IV/V)-A2AR(TM-IV/V) 
model of A2AR-D2R heterodimer. (Electrostatic interactions) Illustration of positively charged 
arginine-rich epitope 215VLRRRRKRVN224 in the N-terminal part of the third intracellular loop of 
D2R electrostatically interacting with the negatively charged C-terminal epitopes of the A2AR 
(370SAQEpSQGNT378, 388HELKGVCPEPPGLDDPLAQDGAGVS412). (Pro-triplet homology 
interactions) In silico analysis and sequence alignment of A2AR and D2R receptor homologies 
containing the triplet homologies AAR, AQE, VLS, and VYI (in red) in the receptor interface. The 
triplet homology VYI is located in the N-terminal of A2AR and in the fifth transmembrane α-helix 
(TM-V) of D2R, the triplet homology VLS is located in the TM-IV of both A2AR and D2R, the triplet 
homology AAR is located in the third intracellular loop (IL3, between TM-V and TM-VI) of both 
A2AR and D2R and the triplet homology AQE is located in the IL3 of D2R and in the C-tail of 
A2AR. Note that the triplet AQE is adjacent to S374 which seems to play a key role in the A2AR-
D2R receptor interfaces. Also note that the triplet VYI cannot play a role since the homology is 
located in the N-terminal part of the A2AR and the fifth TM region of the D2R. (the text and figure 
have been obtained from 27) 
 
1.5 GPCR-RTK receptor-receptor interactions  
It has been observed that the dopamine D2R stimulation of MAPK is mediated by a cell 
type-dependent transactivation of RTK 43. There may also exist RTK ligand independent 
mechanisms for RTK transactivation with participation of both GPCRs and the RTK in a 
multi-receptor signaling complex 55, 56. In fact, D2R agonist enhance the 
coimmunoprecipitation of D2R and EGFRs in neuroblastoma cells, thereby suggesting 
that D2R activation induces the formation of a D2R-EGFR heteroreceptor signalling 
 - 22 - 
complex 43 as a D2/RTK heteromer.   
In addition, a physical interaction between the A2AR and the FGFR1 has been 
demonstrated 45. Coactivation of these two classes of receptors caused a substantially 
increased activation of the MAPK/ERK pathway associated with increases in synaptic 
plasticity with spine morphogenesis. Novel research in this field has increased our 
understanding of the mechanisms of antidepressant drug action and led to the 
development of new strategies for treatment of depression. For the first time it has been 
possible to identify in the mesencephalic 5-HT neurons and their telencephalic targets a 
5-HT1A-FGFR1 heteromer the activation of which may contribute to a relief from 
depression (Borroto-Escuela et al., unpublished data). Ongoing work based on the 
present hypothesis seems to identify that the activation of the 5-HT1A-FGFR1 
heteromer can mediate improvement in 5-HT neuronal communication and 
neurotrophism. Moonlighting in the FGFR1 of the GPCR-FGFR1 heteromers may 
develop as a result of the allosteric receptor-receptor interaction in the heteromer 
achieved inter alia by coactivation of its protomers. This allosteric change in the catalytic 
region of the FGFR1 may change its recruitment of adaptor proteins which may alter the 
pattern of activation of its five major signaling pathways: the RAS/RAF/MAPK 
pathway, the PI3K/AKT/mTOR pathway, the PLC gamma pathway, the JAK/STAT 
pathway, and the IKK/NF-KB pathway. It may be that the receptor-receptor interaction 
may favor the selection of one of its pathways, the RAS/RAF/MAPK pathway, 
according to the results obtained (Borroto-Escuela et al., unpublished data). The results 
open up the exciting possibility that moonlighting in the GPCR-RTK heteromers may 
inter alia lead to altered functions of the RTK protomer with relevance both for trophism 
and neurodegeneration.  
 
1.5.1 Brain FGFR1-5-HT1A heteroreceptor complexes: Implications for major 
depression and its treatment 
The coming together of the serotonin hypothesis and the trophic factor hypothesis of 
depression. 
Coppen introduced the serotonin theory of depression57 in 1967 based inter alia on 
studies on free and total tryptophan, and on brains of depressed suicides. The same 
year Fuxe and Ungerstedt58 demonstrated the 5-HT uptake mechanism of the central 
serotonin neurons, discovered three years earlier59. In 1968 Carlsson, Fuxe and 
Ungerstedt60 reported that imipramine can block the 5-HT uptake mechanism which 
led to the search for serotonin selective reuptake inhibitors SSRIs in the treatment of 
major depression. Today, neurobiological basic research as well as clinical studies on 
SSRIs have further established that the ascending serotonin neuron systems to the 
forebrain are involved in the etiology and therapy of major depression61, 62. The 
therapeutic action of antidepressant drugs is of proven effectiveness, but the 
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mechanisms underlying their effect are still unclear. It is known that, although 
biochemical changes produced by SSRIs occur within hours of administration, 
therapeutic effects become evident only after a latency of about 2–3 weeks, 
suggesting that adaptive processes induced via activation of signaling patterns of 
different 5-HT receptor subtypes, including the regulation of specific genes, are 
necessary for the long-term effects of these drugs. 
According to a current view, antidepressants induce processes of neuroplasticity that 
lead to a reorganization of central neural networks thus and thereby generating their 
therapeutic effects. Increasing evidence suggests that antidepressant drugs via actions 
on the 5-HT neurons may exert their effects on neuroplasticity at least in part, 
through the enhancement of neurotrophic factor expression and function leading to 
therapeutic activity63. A role for fibroblast growth factors (FGFs) has inter alia been 
proposed in mood disorders64. Antidepressant drugs and chronic electroconvulsive 
shock treatment may increase the expression of fibroblast growth factor-2 (FGF-2) in 
frontal cortices and hippocampus. 
Serotonin receptor subtypes and the possible transactivation of the FGF-2/FGFR1 
neurotrophic system 
It seems possible that a certain pattern of activity at different 5-HT receptor subtypes 
of the seven 5-HT receptor families identified is necessary to be induced by SSRIs to 
counteract the depression since some like postjunctional 5-HT1A receptors mediate 
antidepressant activity while others like 5-HT2A receptors mediate depressive 
actions25, 62, 65-67. In contrast, a down-regulation of the inhibitory 5-HT1A 
autoreceptors in the midbrain raphe regions is of importance67, 68.  
The hypothesis was introduced that the neurotrophic system FGF-2/FGFR1 may be a 
good candidate to mediate antidepressant induced improvement in 5-HT neuronal 
communication and neurotrophism with regeneration of connections lost during 
depression63. RTK transactivation in response to antidepressant drug treatment was 
postulated to take place via a new allosteric receptor–receptor interactions between 
distinct serotonin receptor subtypes and FGFR1 heteroreceptor complexes. 
Discovery of hippocampal  FGFR1-5-HT1A heteroreceptor complexes and their 
enhancement of hippocampal plasticity 
By means of several biochemical, biophysical and behavioral assays indications were 
obtained that neurotrophic and antidepressant effects of 5-HT in brain may, in part, 
be mediated by activation of the 5-HT1A receptor protomer in the hippocampal 
FGFR1–5-HT1A receptor complex enhancing the FGFR1 signaling35. Dynamic 
modulation of FGFR1–5-HT1A heteroreceptor complexes was found to exist in 
cellular models42. Agonist treatment enhanced participation of FGFR1 and 5-HT1A 
homodimers in and recruitment of b-arrestin2 to the FGFR1-5-HT 1A heteroreceptor 
complexes42. 
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Discovery of the FGFR1–5-HT1A heteroreceptor complexes in the midbrain raphe 5-
HT nerve cells and their enhancement of the FGFR1 signaling and plasticity 
With in situ PLA and supported by co-location of the FGFR1 and 5-HT1A 
immunoreactivities in midbrain raphe 5-HT cells, evidence for the existence of 
FGFR1–5-HT1A heteroreceptor complexes were obtained in the dorsal and median 
raphe nuclei of the rat69 (Figure 5). The heteroreceptor complex formation was 
dependent on TM5 of the 5-HT1A receptor since it was blocked by incubation with 
TM5 but not with TM2.  
 
 
Figure 5. Illustration of the FGFR1-5-HT1A heteroreceptor complex in the dorsal hippocampus of rat 
brain. Microphotographs from transverse sections of the rat dorsal hippocampus (Bregma level: -3.6 
mm) showing the distribution of the 5-HT1A-FGFR1 heteroreceptor complexes in CA3 using the in 
situ proximity ligation assay (in situ PLA) technique. They are shown as red PLA blobs (clusters) 
found in high densities per cell in a large number of cells in the pyramidal cell layer using confocal 
laser microscopy. The nuclei are shown in blue by DAPI. In the left inset the PLA blobs in the 
pyramidal cell layer are shown in higher magnification. In the lower right part of the figure the 
different parts of the dorsal hippocampus are given in a transverse section. The square outlines the 
CA3 area from which the picture was taken (for further details see 35) Abbreviations: CA3: region III 
of hippocampus proper is a portion of the hippocampal formation. CA stands for the latin cornus 
ammonis. (the text and figure have been taken from 24) 
 
This can be explained based on the triplet puzzle theory70. Namely, the triplet 
homology (protriplet) Gly-Ala-Phe may mediate interaction between TM5 of 5-
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HT1A and TM of FGFR1. Another protriplet Ala-Ala-Arg may also mediate 
interaction 5-HT1A-FGFR1 in the cytoplasmic domain between TM5 and TM6 of 5-
HT1A and substrate binding site of FGFR1. Third protriplet Thr-Leu-Gly in the 
border of this cytoplasmic domain and TM6 of 5-HT1A may also mediate interaction 
5-HT1A-FGFR1.  
The combined i.c.v. treatment with FGF-2 and the 5-HT1A agonist 8-OHDPAT 
synergistically increased FGFR1 and ERK1/2 phosphorylation in the raphe midline 
area of the midbrain and in the raphe RN33B cells. Cotreatment with FGF2 and the 
5-HT1A agonist induced RN33B cell differentiation as seen from development of an 
increased number and length of extensions per cell and their increased 5-HT 
immunoreactivity71. 
 
1.6 Methods for studying receptor-receptor interactions 
The first evidence of GPCRs receptor-receptor interactions was obtained at the 
recognition level of the receptors, using saturation and competition binding experiments 
(Figure 6). The modulation of binding was shown as changes in Kd and Bmax values 
(saturation analysis) and in KL, KH, and RH values (competition analysis) allowing a 
determination of modulation of the high- versus the low-affinity agonist states of the 
receptor. An indication of an effect on the G protein-coupling and thus on the efficacy of 
the modulated receptor could be obtained by studying how, e.g., the modulator could 
control the GTP-induced disappearance of the high-affinity state of the receptor 
(reduction of the RH values). 
FRET and BRET methods gave the evidence needed to demonstrate heteromers among 
class A GPCRs (Figure 6). Schematic representation of the basic principle of FRET are 
displayed here. Two putative proteins (A and B) bearing a ‘donor’ (CFP) or an 
‘acceptor’ (YFP) fluorophore are depicted. If these two proteins interact then the donor 
and acceptor fluorophores are likely in proximity (10 nm or less) and energy transfer 
between donor and acceptor can occur after donor excitation by demonstration of YFP 
emission. Two putative proteins (A and B) bearing a ‘donor’ (Rluciferase, Rluc) or an 
‘acceptor’ fluorophore (YFP) are depicted. If these proteins are in proximity, e.g. do 
interact, then a donor-acceptor energy transfer can occur after Rluc substrate (h-
coelenterazine) oxidation. The bioluminescence formed can activate YFP and YFP 
emission develops. 
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Figure 6. Different methods have been used to study GPCR homo and heteroreceptor complexes. As 
examples are shown methods used to study the existence of A2A-D2 heteroreceptor complexes in 
heterologous expression systems and in brain ex vivo. (A) Competition experiments using D2-like 
receptor antagonist [3H]-Raclopride (2 nM) versus increasing concentrations of dopamine in transiently 
cotransfected HEK293T cell membranes. Panel A illustrates the right shift of the competition curve 
after treatment with the A2A agonist CGS21680 in the high affinity range of the D2R agonist binding 
site demonstrating a reduction of D2R affinity in the high affinity state (B) Detection of A2A-D2 
heteroreceptor complexes in ex vivo brain sections can be found by in situ proximity ligation assay 
(PLA). PLA-positive A2A-D2 heteroreceptor complexes in striatal sections have been visualized as 
red clusters (blobs, dots) within the neuropil of caudate putamen (CPu) which were almost absent 
within the external capsule (ec). (C) In C the principle of the BRET1 method is illustrated giving strong 
support for the existence of A2AR-D2R heteromers. In the presence of h-coelenterazine, an energy 
transfer between Rluc and YFP occurs when the distance between them is less than 100 Å. To the right 
a BRET1 saturation curve for the A2A-D2   hetero receptor complex (D2LRRluc + A2ARYFP, filled 
circles) is shown giving BRET max and BRET EC50 values27. (The text and the figure have been 
obtained from 27) 
 
Fluorescence resonance energy transfer (FRET) and bioluminescence resonance 
energy transfer (BRET) methods were introduced which could be used to study homo 
and heteromerization of proteins including receptors in living cells. It involved the 
preparations of receptor constructs having genetically fused ‘donor’ and ‘acceptor’ 
fluorescent proteins.  
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In FRET if the donor and acceptor fluorophores are in close proximity (less than 
10nm) energy transfer between the two fluorophores can occur after donor excitation 
and acceptor emission develops 83, 84. Energy transfer is inversely proportional to the 
sixth power of the distance (r) between donor and acceptor fluorophors and the 
distance leading to 50% of energy transfer from the donor to the acceptor is around 
5nm. There are drawbacks of using classical FRET when the protein is located in 
intracellular stores, making measurements of protein interactions at the plasma 
membrane difficult.  
However, there exist cell surface FRET detection technologies to study GPCR 
heteromerization in the plasma membrane 51. Using the total internal reflection 
fluorescence microscopy (TIRF) approach it is possible to narrow and better define 
the field of excitation. The light decays in an exponential way and is restricted in 
terms of  distance propagation, for instance, appropriate fluorophores can be excite 
only within a distance of 100nm 83. With cell surface TIRF-FRET detection 
technology a collimated light at an angle of projection exceeding a critical angle 
generates at the cover slip surface an evanescent field, the light of which decays 
exponentially, penetrating into the cell only approximately 100nm. 
There is also the technique of bimolecular fluorescence complementation (BiFC) to 
demonstrate protein dimerization. Two putative proteins (A and B) can carry N-YFP 
and C-YFP halves, respectively. If a dimerization/interaction phenomenon between 
A and B takes place, then a fluorescent fusion complex of the two complemented 
fragments of the YFP protein (N and C) will be generated. And thereby, allowing a 
direct visualization of dimerization of A and B after the excitation of the YFP 
reconstructed protein 46, 85. 
The principle of the detection of GPCR heterodimerization using the BRET method 
is similar to FRET. In the presence of the substrate h-coelenterazine or 
coelenterazine-400 on which Renilla luciferase fused to the donor acts to produce 
through their oxidation a compound showing bioluminence. An energy transfer 
between the generated luminescence and YFP or GFP2 occurs when the distance 
between these proteins is less than 10nm. This leads to a fluorescence emission from 
YFP (BRET1) or GFP2 (BRET2) representing the BRET signal. BRET gives strong 
support for the existence of receptor heteromers in artificial cell systems. 
In titration or saturation BRET2 experiments cells are transfected with a constant 
amount of BRET2-donor in presence or absence of increasing amounts of the 
acceptor. Theoretically, for any specific interaction between the Receptor-donor and 
Receptor-acceptor fusions, the BRET2 ratio signal is developed as an hyperbole 
function of GFP/Rluc values, reaching an asymptote (saturation) when all donor 
molecules are associated with acceptors (BRETmax) 48, 86, 87. 
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The BRETmax values are influenced by several parameters or factors, e.g., on the 
energy transfer distance between receptor protomers, their relative orientation and the 
dimer numbers. Therefore, these values cannot be used as a quantitative measure of 
the relative number of receptor complex formed. BRET2 saturation curves have been 
particularly used with the aim to establish the oligomeric order of receptor 
complexes, as well as the proportion of receptors engaged in dimers or oligomers. 
They are also used to determine whether ligand-induced BRET2 signals depend on 
conformational changes or association/dissociation of interacting receptors. Also 
saturation assays have been used to compare the relative affinity of receptors for each 
other and their probability to form a complex, the so called BRET50, which represents 
the acceptor/donor ratio giving 50% of the maximal signal. This value could also be 
used to compare the homo vs heterodimer affinity relationships 87. Many GPCR-
GPCR heteromers show no difference in the relative affinity between their receptor 
homomers and their specific heteromers. Furthermore, neither BRETmax nor BRET50 
values may be modified following the agonist activation of the heteromer, consistent 
with the general consensus that GPCR homo- and heteromerization is often 
constitutive. In contrast, GPCR-RTK heteroreceptor complexes show more dynamic 
features where agonist treatment markedly affect BRETmax, BRET50 or both these 
values 35, 42, 48. 
Over the last years different generations of BRET (BRET1, BRET2, eBRET2, BRET3 
and QD-BRET) have been developed, depending on the type of enzyme substrate and 
the nature of donor/acceptor pairs. As a result, the nomenclature for describing each 
of the BRET forms has not followed a unique rigorous pattern. 
In our work we often used the BRET2 variant assay with Rluc8 as a donor and GFP2 
as an acceptor with improved spectral separation of the donor bioluminescence and 
acceptor emission peaks. This implies less bleed-through at the acceptor emission 
maximum and lower background. Also, the rational for the use of mutated Rluc 
(Rluc8, Genbank: EF446136) instead of the non-mutated Rluc is mainly based on the 
fact that Rluc8 gives a higher quantum yield compared to the non-mutated Rluc. 
Therefore, we do not need to overexpress the luciferase fusion receptor which is 
detrimental for interaction specificity. 
Detection of higher order heteroreceptor complexes can be obtained by combined 
BRET/BiFC assays in which BiFC is followed by BRET. It may be achieved by 
combining the bimolecular fluorescence complementation with BRET 47, 72. The 
trimeric heteromers of GPCRs can also be demonstrated with a combination of 
BRET and FRET. It is called the sequential BRET-FRET technique or SRET 
technique 73. In SRET2 you use the blue bioluminenscence from deep blueC which 
activates the GFP2 (BRET2) and its emission activates the yellow fluorescent protein 
which is the FRET component. In SRET1 you use instead BRET1which involves 
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addition of the Rluc substrate coelenterazine h and energy transfer to YFP. This is 
followed by FRET transfer to the DsRed acceptor fluorescent protein and elicitation 
of emission in the red range. Also, the sequential BRET–FRET methods is used for 
the demonstration of the higher-order heteroreceptor complex in like the A2A-D2-
CB1 complex. 
Taken together, the use of FRET and BRET-based techniques emerged as important 
tools in the analysis of GPCR dimerization in living cells. Nevertheless there are 
inherent problems linked to the use of these technologies. For instance, the 
attachment of such large fluorescent proteins may block proper receptor function, 
which makes it difficult to interpret of results. In addition, the existence of false 
FRET and BRET signals produced by photophysic cross-talks should be considered. 
An increase of non-specific FRET and BRET can take place as a result of the random 
collision of intracellularly accumulated FRET or BRET-tagged receptors when 
transiently overexpressed. In view of this some controversy surrounds these 
approaches 77, 78. Nevertheless, when FRET and BRET-based results are properly 
evaluated, we can demonstrate clearly an oligomerization of heterologously 
expressed GPCRs and of cells from transgenic animals 48, 78-81. Consensus exists that 
FRET and BRET methods powerfully support the existence of receptor heteromers in 
living cells 82. 
In situ Proximity Ligation Assay (in situ PLA) has been performed to establish the 
existence of native heteroreceptor complexes in the CNS 35, 49, 89, 90. In situ PLA is 
based on a pair of primary antibodies followed by the use of secondary antibodies to 
which oligonucleotides have been linked. When the two antibodies recognize a 
dimer, the oligonucleotides of the secondary antibodies are in a sufficiently close 
proximity (16nm or less) to allow them to recognize each other and join followed by 
an enzymatic ligation reaction. Then, the DNA circle strand formed can act as a 
template for an amplification reaction of the rolling circle. It is linked to one of the 
proximity probes and can be detected and quantified by hybridizing fluorescent 
oligonucleotides. This sequential reaction process (antibody recognition, joining of 
oligonucleotides, ligation, amplification and hybridization) rendered the 
heteroreceptor complexes observable by fluorescence microscopy. In this way you 
can study the number, localization and modulation of CNS heteroreceptor complexes 
since formalin fixed tissue is used 10, 35, 49, 74, 75, 89-91. The main drawback of in situ 
PLA lies in the quality of fixed tissue, the specificity and bivalent character of the 
primary antibodies and the use of  proper controls. 
Taken together, the findings indicate that in situ PLA can be used to demonstrate 
heteroreceptor complexes ex vivo in brain tissue like the striatal A2A-D2 
heteroreceptor complexes 49, 89 and the accumbal and dorsal striatal D2-5HT2A 
heteroreceptor complexes 91.  
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AIMS 
 
The overall aim of this thesis was to gain insight into molecular aspects of the 
dopamine D2 and serotonin 5-HT1A heteroreceptor complexes and their allosteric 
receptor-receptor interaction in the Central Nervous System in view of the relevant 
role of both receptor on several mental and neurological diseases. The following 
specific aims were considered:  
 
! To explore the role of negatively charged double aspartates (D401A-D402A) 
and single serine (S374A) in the A2AR-D2R interface and their impact on the 
allosteric mechanisms operating on the A2AR-D2R heteroreceptor complexes . 
Also to confirm the role of the TM helix interactions of the A2AR-D2R 
interface using TM synthetic peptides and  BRET1 saturation and competition 
assays. Furthermore, based on the experimental results, and using a novel 
bioinformatics approach to predict the receptor-receptor interface, to perform a 
molecular dynamic simulation and a rigid-body protein-protein docking of the 
A2AR-D2R heteromers (Chapter 1 and 4).  
! To validate that D2R form heteroreceptor complex with NTS1R and determine 
their ratios to total D2R or NTS1R populations in accumbens and dorsal 
striatal sections and primary striatal cultures through molecular assessment 
using in situ proximity ligation assay supported with coimmunoprecipitation 
data and bioluminescence and fluorescence resonance energy transfer methods 
(BRET/FRET). To further validate the allosteric mechanisms and the  dynamic 
changes in D2R signalling in D2R-NTS1R heteroreceptor complexes upon 
agonist activation of NTS1R using gene reporter assays to follow the adenylyl 
cyclase (AC) and MAPK activities in line with the previous findings of an 
NTS1R mediated antagonistic regulation of D2R recognition (Chapter 2). 
! To study the dynamic modulation of 5-HT1A-FGFR1 heteroreceptor 
complexes using the BRET2 assay in HEK293T cells. Also, to understand the 
role and participation of 5-HT1A and FGFR1 homoreceptor complexes and 
recruitment of β-rrestin2 upon agonist treatment (Chapter 3 and 5). 
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CHAPTERS 1-5 
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CONCLUSIONS 
 
I. A single serine point mutation (S374A) in the adenosine A2A receptor (A2AR) C-
terminal tail reduces A2AR-D2R heteromerization and prevents its allosteric 
modulation of the dopamine D2 receptor (D2R). We found evidence that the TM 
domains IV and V of the D2R play a major role in the A2AR-D2R heteromer 
interface since the incubation with peptides corresponding to these domains 
significantly reduced the ability of A2AR and D2R to form a heteroreceptor 
complexe. In addition, the incubation with TM-IV or TM-V blocked the 
allosteric modulation normally found in A2AR-D2R heteromers. The mutation of 
two negatively charged aspartates in the A2AR C-terminal tail (D401A/D402A) 
in combination with the S374A mutation drastically reduced the physical A2AR-
D2R interaction and lost the ability of antagonistic allosteric modulation over the 
A2AR-D2R interface, suggesting further evidence for the existence of an 
electrostatic interaction between the C-terminal tail of A2AR and the intracellular 
loop 3 (IL3) of D2R. On the other hand, molecular dynamic model and 
bioinformatic analysis propose that specific AAR, AQE, and VLS protriplets as 
an important motive in the A2AR-D2LR heteromer interface together with D2LR 
TM segments IV/V interacting with A2AR TM-IV/V or TM-I/VII. 
 
II. Biochemical, histochemical and coimmunoprecipitation experiments have 
indicated the existence of antagonistic dopamine D2 (D2R) and neurotensin 1 
(NTS1R) receptor-receptor interactions in the dorsal and ventral striatum 
suggesting a potential role of these receptor-receptor interactions in Parkinson’s 
disease and schizophrenia. By means of Bioluminiscence Resonance energy 
transfer (BRET2) evidence has for the first time been obtained in the current 
study for the existence of both D2LR/NTS1R and D2SR/NTS1R heteroreceptor 
complexes in living HEK293T cells. Through confocal laser microscopy the 
NTS1RGFP2 and D2RYFP were also shown to be colocated in the plasma 
membrane of these cells. A bioinformatic analysis suggests the existence of a 
basic set of three homology protriplets (TVM, DLL and/or LRA) in the two 
participating receptors which may contribute to the formation of the D2R/NTS1R 
heteromers by participating in guide-clasp interactions in the receptor interface. 
The CREB reporter gene assay indicated that the neurotensin receptor agonist 
JMV 449 markedly reduced the potency of the D2R like agonist quinpirole to 
inhibit the forskolin induced increase of the CREB signal. In contrast, the 
neurotensin agonist was found to markedly increase the quinpirole potency to 
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activate the MAPK pathway as also studied with luciferase reporter gene assay 
measuring the degree of SRE activity as well as with ERK1/2 phosphorylation 
assays. These dynamic changes in D2R signaling produced by the neurotensin 
receptor agonist may involve antagonistic allosteric receptor-receptor 
interactions in the D2LR-NTS1R heteromers at the plasma membrane level 
(CREB pathway) and synergistic interactions in PKC activation at the 
cytoplasmatic level (MAPK pathway). 
 
III. New findings show that neurotrophic and antidepressant effects of 5-HT in brain 
can, in part, be mediated by activation of the 5-HT1A receptor protomer in the 
hippocampal and raphe FGFR1-5-HT1A heteroreceptor complexes enhancing 
the FGFR1 signaling. The dynamic agonist modulation of the FGFR1-5-HT1A 
heteroreceptor complexes and their recruitment of β-arrestin is now determined 
in cellular models with focus on its impact on 5-HT1AR and FGFR1 
homodimerization in the heteroreceptor complexes based on BRET2 assays. The 
findings show that coagonist treatment with 8-OH-DPAT and FGF2 but not 
treatment with the 5-HT1A agonist alone markedly increases the BRETmax 
values and significantly reduces the BRET50 values of 5HT1A 
homodimerization. The effects of FGF2 or FGF20 with or without the 5-HT1A 
agonist were also studied on the FGFR1 homodimerization of the heteroreceptor 
complexes. FGF2 produced a marked and rapid increase in FGFR1 
homodimerization which partially declined over a 10 min period. Cotreatment 
with FGF2 and 5-HT1A agonist blocked this decline in FGFR1 
homodimerization. Furthermore, FGF2 alone produced a small increase in the 
BRET2 signal from the 5-HT1A-β-arrestin2 receptor-protein complex which was 
additive to the marked effect of 8-OH-DPAT alone. Taken together, the results 
indicate a dynamic agonist regulation of the FGFR1-5-HT1A heteroreceptor 
complexes, which via allosteric receptor-receptor interactions leads to a 
structural change in this heteroreceptor complex. This change results in an 
expanded FGFR-5-HT1A heteroreceptor complex in which an increased 
presence of FGFR1 and 5-HT1A homodimers develops. Thus, the agonist 
regulation of these heteroreceptor complexes produces a reorganization in their 
structure to include an increased participation of FGFR1 and 5-HT1A 
homodimers and recruitment of β-arrestin2 to the 5-HT1A and also to the 
FGFR1 protomers. 
 
 
 
 - 34 - 
 
REFERENCES 
 
1. Fuxe, K. et al. Evidence for the existence of receptor--receptor interactions in 
the central nervous system. Studies on the regulation of monoamine receptors 
by neuropeptides. J Neural Transm Suppl 18, 165-79 (1983). 
2. Fuxe, K. & Agnati, L.F. Receptor-receptor interactions in the central nervous 
system. A new integrative mechanism in synapses. Med Res Rev 5, 441-82 
(1985). 
3. Fuxe, K. et al. Diversity and Bias through Receptor-Receptor Interactions in 
GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 
Receptor Heteromerization. Front Endocrinol (Lausanne) 5, 71 (2014). 
4. Fuxe, K. et al. Dopamine D2 heteroreceptor complexes and their receptor-
receptor interactions in ventral striatum: novel targets for antipsychotic drugs. 
Prog Brain Res 211, 113-39 (2014). 
5. Fuxe, K. & Agnati, L. Receptor-receptor interactions. A new intramembrane 
integrative mechanism (Macmillan Press, London, 1987). 
6. Borroto-Escuela, D.O. et al. Multiple D2 heteroreceptor complexes: new 
targets for treatment of schizophrenia. Ther Adv Psychopharmacol 6, 77-94 
(2016). 
7. Borroto-Escuela, D.O. & Fuxe, K. Diversity and bias through dopamine D2R 
heteroreceptor complexes. Curr Opin Pharmacol 32, 16-22 (2016). 
8. Fuxe, K., Guidolin, D., Agnati, L.F. & Borroto-Escuela, D.O. Dopamine 
heteroreceptor complexes as therapeutic targets in Parkinson's disease. Expert 
Opin Ther Targets 19, 377-98 (2015). 
9. George, S.R., Kern, A., Smith, R.G. & Franco, R. Dopamine receptor 
heteromeric complexes and their emerging functions. Prog Brain Res 211, 
183-200 (2014). 
10. Romero-Fernandez, W., Borroto-Escuela, D.O., Agnati, L.F. & Fuxe, K. 
Evidence for the existence of dopamine D2-oxytocin receptor heteromers in 
the ventral and dorsal striatum with facilitatory receptor-receptor interactions. 
Mol Psychiatry 18, 849-50 (2013). 
11. Fuxe, K. et al. Modulation by cholecystokinins of 3H-spiroperidol binding in 
rat striatum: evidence for increased affinity and reduction in the number of 
binding sites. Acta Physiol Scand 113, 567-9 (1981). 
12. Fuxe, K., Agnati, L., Ogren, S.O., Andersson, K. & Benfenati, F. in Neural 
transmission, learning and memory (eds. Caputto, R. & Marsan, C.) 237-255 
(Raven Press, New York, 1983). 
13. Limbird, L.E., Meyts, P.D. & Lefkowitz, R.J. Beta-adrenergic receptors: 
evidence for negative cooperativity. Biochem Biophys Res Commun 64, 1160-
8 (1975). 
14. Limbird, L.E. & Lefkowitz, R.J. Negative cooperativity among beta-
adrenergic receptors in frog erythrocyte membranes. J Biol Chem 251, 5007-
14 (1976). 
15. Zoli, M. et al. Receptor-receptor interactions as an integrative mechanism in 
nerve cells. Mol Neurobiol 7, 293-334 (1993). 
 - 35 - 
16. Fraser, C.M. & Venter, J.C. The size of the mammalian lung beta 2-
adrenergic receptor as determined by target size analysis and immunoaffinity 
chromatography. Biochem Biophys Res Commun 109, 21-9 (1982). 
17. Paglin, S. & Jamieson, J.D. Covalent crosslinking of angiotensin II to its 
binding sites in rat adrenal membranes. Proc Natl Acad Sci U S A 79, 3739-
43 (1982). 
18. Yarden, Y. & Schlessinger, J. Epidermal growth factor induces rapid, 
reversible aggregation of the purified epidermal growth factor receptor. 
Biochemistry 26, 1443-51 (1987). 
19. White, J.H. et al. Heterodimerization is required for the formation of a 
functional GABA(B) receptor. Nature 396, 679-82 (1998). 
20. Marshall, F.H., White, J., Main, M., Green, A. & Wise, A. GABA(B) 
receptors function as heterodimers. Biochem Soc Trans 27, 530-5 (1999). 
21. Marshall, F.H. Is the GABA B heterodimer a good drug target? J Mol 
Neurosci 26, 169-76 (2005). 
22. Agnati, L.F., Ferre, S., Lluis, C., Franco, R. & Fuxe, K. Molecular 
mechanisms and therapeutical implications of intramembrane 
receptor/receptor interactions among heptahelical receptors with examples 
from the striatopallidal GABA neurons. Pharmacol Rev 55, 509-50 (2003). 
23. Fuxe, K. & Borroto-Escuela, D.O. Heteroreceptor Complexes and their 
Allosteric Receptor-Receptor Interactions as a Novel Biological Principle for 
Integration of Communication in the CNS: Targets for Drug Development. 
Neuropsychopharmacology 41, 380-2 (2016). 
24. Borroto-Escuela, D.O., Tarakanov, A.O. & Fuxe, K. FGFR1-5-HT1A 
Heteroreceptor Complexes: Implications for Understanding and Treating 
Major Depression. Trends Neurosci 39, 5-15 (2016). 
25. Borroto-Escuela, D.O. et al. The role of transmitter diffucsion and flow 
versus extracellular vesicles in volume transmission in the brain neural-glial 
networks. Phil. Tans. R. Soc. B (2015). 
26. Guidolin, D., Agnati, L.F., Marcoli, M., Borroto-Escuela, D.O. & Fuxe, K. G-
protein-coupled receptor type A heteromers as an emerging therapeutic target. 
Expert Opin Ther Targets 19, 265-83 (2015). 
27. Fuxe, K. et al. Moonlighting proteins and protein-protein interactions as 
neurotherapeutic targets in the G protein-coupled receptor field. 
Neuropsychopharmacology 39, 131-55 (2014). 
28. Fuxe, K., Borroto-Escuela, D., Fisone, G., Agnati, L.F. & Tanganelli, S. 
Understanding the role of heteroreceptor complexes in the central nervous 
system. Curr Protein Pept Sci 15, 647 (2014). 
29. Fuxe, K., Agnati, L.F. & Borroto-Escuela, D.O. The impact of receptor-
receptor interactions in heteroreceptor complexes on brain plasticity. Expert 
Rev Neurother 14, 719-21 (2014). 
30. Jeffery, C.J. Moonlighting proteins: old proteins learning new tricks. Trends 
Genet 19, 415-7 (2003). 
31. Jeffery, C.J. Moonlighting proteins. Trends Biochem Sci 24, 8-11 (1999). 
32. Borroto-Escuela, D.O. et al. The G protein-coupled receptor heterodimer 
network (GPCR-HetNet) and its hub components. Int J Mol Sci 15, 8570-90 
(2014). 
33. Fuxe, K. et al. Receptor heteromerization in adenosine A2A receptor 
signaling: relevance for striatal function and Parkinson's disease. Neurology 
61, S19-23 (2003). 
 - 36 - 
34. Fuxe, K. et al. Integrated signaling in heterodimers and receptor mosaics of 
different types of GPCRs of the forebrain: relevance for schizophrenia. J 
Neural Transm 116, 923-39 (2009). 
35. Borroto-Escuela, D.O. et al. Fibroblast growth factor receptor 1- 5-
hydroxytryptamine 1A heteroreceptor complexes and their enhancement of 
hippocampal plasticity. Biol Psychiatry 71, 84-91 (2012). 
36. Filip, M., Zaniewska, M., Frankowska, M., Wydra, K. & Fuxe, K. The 
importance of the adenosine A(2A) receptor-dopamine D(2) receptor 
interaction in drug addiction. Curr Med Chem 19, 317-55 (2012). 
37. Fuxe, K., Marcellino, D., Genedani, S. & Agnati, L. Adenosine A(2A) 
receptors, dopamine D(2) receptors and their interactions in Parkinson's 
disease. Mov Disord 22, 1990-2017 (2007). 
38. Schwarzschild, M.A., Agnati, L., Fuxe, K., Chen, J.F. & Morelli, M. 
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 
29, 647-54 (2006). 
39. Guo, W. et al. Dopamine D2 receptors form higher order oligomers at 
physiological expression levels. EMBO J 27, 2293-304 (2008). 
40. Han, Y., Moreira, I.S., Urizar, E., Weinstein, H. & Javitch, J.A. Allosteric 
communication between protomers of dopamine class A GPCR dimers 
modulates activation. Nat Chem Biol 5, 688-95 (2009). 
41. Borroto-Escuela, D.O. et al. Enhancement of the FGFR1 signaling in the 
FGFR1-5-HT1A heteroreceptor complex in midbrain raphe 5-HT neuron 
systems. Relevance for neuroplasticity and depression. Biochem Biophys Res 
Commun 463, 180-6 (2015). 
42. Borroto-Escuela, D.O. et al. Dynamic modulation of FGFR1-5-HT1A 
heteroreceptor complexes. Agonist treatment enhances participation of 
FGFR1 and 5-HT1A homodimers and recruitment of beta-arrestin2. Biochem 
Biophys Res Commun 441, 387-92 (2013). 
43. Wang, C., Buck, D.C., Yang, R., Macey, T.A. & Neve, K.A. Dopamine D2 
receptor stimulation of mitogen-activated protein kinases mediated by cell 
type-dependent transactivation of receptor tyrosine kinases. J Neurochem 93, 
899-909 (2005). 
44. Fuxe, K. et al. From the Golgi-Cajal mapping to the transmitter-based 
characterization of the neuronal networks leading to two modes of brain 
communication: wiring and volume transmission. Brain Res Rev 55, 17-54 
(2007). 
45. Flajolet, M. et al. FGF acts as a co-transmitter through adenosine A(2A) 
receptor to regulate synaptic plasticity. Nat Neurosci 11, 1402-9 (2008). 
46. Vidi, P.A., Chen, J., Irudayaraj, J.M. & Watts, V.J. Adenosine A(2A) 
receptors assemble into higher-order oligomers at the plasma membrane. 
FEBS Lett 582, 3985-90 (2008). 
47. Navarro, G. et al. Detection of heteromers formed by cannabinoid CB1, 
dopamine D2, and adenosine A2A G-protein-coupled receptors by combining 
bimolecular fluorescence complementation and bioluminescence energy 
transfer. ScientificWorldJournal 8, 1088-97 (2008). 
48. Borroto-Escuela, D.O., Flajolet, M., Agnati, L.F., Greengard, P. & Fuxe, K. 
Bioluminescence resonance energy transfer methods to study G protein-
coupled receptor-receptor tyrosine kinase heteroreceptor complexes. Methods 
Cell Biol 117, 141-64 (2013). 
 - 37 - 
49. Trifilieff, P. et al. Detection of antigen interactions ex vivo by proximity 
ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes 
in the striatum. Biotechniques 51, 111-8 (2011). 
50. Borroto-Escuela, D.O. et al. in G Protein Coupled Receptors (ed. Conn, M.) 
480 (Academic Press, 2013). 
51. Fernandez-Duenas, V. et al. Molecular determinants of A2AR-D2R 
allosterism: role of the intracellular loop 3 of the D2R. J Neurochem 123, 
373-84 (2012). 
52. Borroto-Escuela, D.O. et al. A serine point mutation in the adenosine A2AR 
C-terminal tail reduces receptor heteromerization and allosteric modulation of 
the dopamine D2R. Biochem Biophys Res Commun 394, 222-7 (2010). 
53. Borroto-Escuela, D.O. et al. On the existence of a possible A2A-D2-beta-
Arrestin2 complex: A2A agonist modulation of D2 agonist-induced beta-
arrestin2 recruitment. J Mol Biol 406, 687-99 (2011). 
54. Borroto-Escuela, D.O. et al. Characterization of the A2AR-D2R interface: 
focus on the role of the C-terminal tail and the transmembrane helices. 
Biochem Biophys Res Commun 402, 801-7 (2010). 
55. Maudsley, S. et al. The beta(2)-adrenergic receptor mediates extracellular 
signal-regulated kinase activation via assembly of a multi-receptor complex 
with the epidermal growth factor receptor. J Biol Chem 275, 9572-80 (2000). 
56. Wetzker, R. & Bohmer, F.D. Transactivation joins multiple tracks to the 
ERK/MAPK cascade. Nat Rev Mol Cell Biol 4, 651-7 (2003). 
57. Coppen, A. The biochemistry of affective disorders. Br J Psychiatry 113, 
1237-64 (1967). 
58. Fuxe, K. & Ungerstedt, U. Localization of 5-hydroxytryptamine uptake in rat 
brain after intraventricular injection. J Pharm Pharmacol 19, 335-7 (1967). 
59. Dahlstroem, A. & Fuxe, K. Evidence for the Existence of Monoamine-
Containing Neurons in the Central Nervous System. I. Demonstration of 
Monoamines in the Cell Bodies of Brain Stem Neurons. Acta Physiol Scand 
Suppl, SUPPL 232:1-55 (1964). 
60. Carlsson, A., Fuxe, K. & Ungerstedt, U. The effect of imipramine on central 
5-hydroxytryptamine neurons. J Pharm Pharmacol 20, 150-1 (1968). 
61. Blier, P. Neurotransmitter targeting in the treatment of depression. J Clin 
Psychiatry 74 Suppl 2, 19-24 (2013). 
62. Hamon, M. & Blier, P. Monoamine neurocircuitry in depression and 
strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 
45, 54-63 (2013). 
63. Fuxe, K. et al. From the Golgi-Cajal mapping to the transmitter-based 
characterization of the neuronal networks leading to two modes of brain 
communication: wiring and volume transmission. Brain Res Rev 55, 17-54 
(2007). 
64. Turner, C.A., Akil, H., Watson, S.J. & Evans, S.J. The fibroblast growth 
factor system and mood disorders. Biol Psychiatry 59, 1128-35 (2006). 
65. Fuxe, K. et al. in Galanin: a new multifunctional peptide in the 
neuroendocrine system (eds. Hokfelt, T., Bartfai, T., Jacobowitz, D.M. & 
Ottoson, D.) 221-235 (MacMillan Press, London, 1991). 
66. Alvarez, E., Perez, V. & Artigas, F. Pharmacology and clinical potential of 
vortioxetine in the treatment of major depressive disorder. Neuropsychiatr 
Dis Treat 10, 1297-307 (2014). 
 - 38 - 
67. Artigas, F. Developments in the field of antidepressants, where do we go 
now? Eur Neuropsychopharmacol 25, 657-70 (2015). 
68. Albert, P.R., Vahid-Ansari, F. & Luckhart, C. Serotonin-prefrontal cortical 
circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-
synaptic 5-HT1A receptor expression. Front Behav Neurosci 8, 199 (2014). 
69. Borroto-Escuela, D.O. et al. Evidence for the existence of FGFR1-5-HT1A 
heteroreceptor complexes in the midbrain raphe 5-HT system. Biochem 
Biophys Res Commun 456, 489-93 (2015). 
70. Borroto-Escuela, D.O. et al. Dopamine D2 and D4 receptor heteromerization 
and its allosteric receptor-receptor interactions. Biochem Biophys Res 
Commun 404, 928-34 (2010). 
71. Borroto-Escuela, D.O. et al. Enhancement of the FGFR1 signaling in the 
FGFR1-5-HT1A heteroreceptor complex in midbrain raphe 5-HT neuron 
systems. Relevance for neuroplasticity and depression. Biochem Biophys Res 
Commun (2015). 
72. Cabello, N. et al. Metabotropic glutamate type 5, dopamine D2 and adenosine 
A2a receptors form higher-order oligomers in living cells. J Neurochem 109, 
1497-507 (2009). 
73. Carriba, P. et al. Detection of heteromerization of more than two proteins by 
sequential BRET-FRET. Nat Methods 5, 727-33 (2008). 
74. Soderberg, O. et al. Direct observation of individual endogenous protein 
complexes in situ by proximity ligation. Nat Methods 3, 995-1000 (2006). 
75. Soderberg, O. et al. Proximity ligation: a specific and versatile tool for the 
proteomic era. Genet Eng (N Y) 28, 85-93 (2007). 
76. Romero-Fernandez, W., Borroto-Escuela, D.O., Agnati, L.F. & Fuxe, K. 
Evidence for the existence of dopamine d2-oxytocin receptor heteromers in 
the ventral and dorsal striatum with facilitatory receptor-receptor interactions. 
Mol Psychiatry (2012). 
77. James, J.R., Oliveira, M.I., Carmo, A.M., Iaboni, A. & Davis, S.J. A rigorous 
experimental framework for detecting protein oligomerization using 
bioluminescence resonance energy transfer. Nat Methods 3, 1001-6 (2006). 
78. Bouvier, M., Heveker, N., Jockers, R., Marullo, S. & Milligan, G. BRET 
analysis of GPCR oligomerization: newer does not mean better. Nat Methods 
4, 3-4; author reply 4 (2007). 
79. Marullo, S. & Bouvier, M. Resonance energy transfer approaches in 
molecular pharmacology and beyond. Trends Pharmacol Sci 28, 362-5 
(2007). 
80. Pin, J.P. et al. International Union of Basic and Clinical Pharmacology. 
LXVII. Recommendations for the recognition and nomenclature of G protein-
coupled receptor heteromultimers. Pharmacol Rev 59, 5-13 (2007). 
81. Audet, M., Lagace, M., Silversides, D.W. & Bouvier, M. Protein-protein 
interactions monitored in cells from transgenic mice using bioluminescence 
resonance energy transfer. FASEB J 24, 2829-38 (2010). 
82. Ferre, S. et al. Building a new conceptual framework for receptor heteromers. 
Nat Chem Biol 5, 131-4 (2009). 
83. Kaczor, A.A. & Selent, J. Oligomerization of G protein-coupled receptors: 
biochemical and biophysical methods. Curr Med Chem 18, 4606-34 (2011). 
84. Castro, B.M., Torreno-Pina, J.A., van Zanten, T.S. & Gracia-Parajo, M.F. 
Biochemical and imaging methods to study receptor membrane organization 
and association with lipid rafts. Methods Cell Biol 117, 105-22 (2013). 
 - 39 - 
85. Vidi, P.A. & Watts, V.J. Fluorescent and bioluminescent protein-fragment 
complementation assays in the study of G protein-coupled receptor 
oligomerization and signaling. Mol Pharmacol 75, 733-9 (2009). 
86. Hamdan, F.F., Percherancier, Y., Breton, B. & Bouvier, M. Monitoring 
protein-protein interactions in living cells by bioluminescence resonance 
energy transfer (BRET). Curr Protoc Neurosci Chapter 5, Unit 5 23 (2006). 
87. Borroto-Escuela, D.O., Garcia-Negredo, G., Garriga, P., Fuxe, K. & Ciruela, 
F. The M(5) muscarinic acetylcholine receptor third intracellular loop 
regulates receptor function and oligomerization. Biochim Biophys Acta 1803, 
813-25 (2010). 
88. Albizu, L. et al. Time-resolved FRET between GPCR ligands reveals 
oligomers in native tissues. Nat Chem Biol 6, 587-94 (2010). 
89. Borroto-Escuela, D.O. et al. G protein-coupled receptor heterodimerization in 
the brain. Methods Enzymol 521, 281-94 (2013). 
90. Borroto-Escuela, D.O. et al. Dopamine D2 and D4 receptor heteromerization 
and its allosteric receptor-receptor interactions. Biochem Biophys Res 
Commun 404, 928-34 (2011). 
91. Borroto-Escuela, D.O. et al. Hallucinogenic 5-HT2AR agonists LSD and DOI 
enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A 
heteroreceptor complexes. Biochem Biophys Res Commun 443, 278-84 
(2014). 
92. Borroto-Escuela, D.O. et al. Preferential activation by galanin 1-15 fragment 
of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex. Biochem 
Biophys Res Commun 452, 347-53 (2014). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 - 40 - 
 
ACKNOLEDGMENTS 
 
I’d like to thank to my supervisors for giving me the unique opportunity to get trained 
within one of the most prestigious medical universities worldwide such as Karolinska 
Institutet and also the University of Malaga.  
Furthermore, I’m greatly grateful to Fuxe lab team members and for their precious 
teachings, friendship and kindness. 
Obviously a huge thank goes also to my mother and my grandfather for making it 
possible. 
I’m also extremely thankful my Bayolo for the strength he infused in me and for his 
never missing support. 
Last but not least, many thanks to my home town friends as well as University of 
Havana, Centro Nacional de Neurociencias and Karolinska Institutet’s ones for being 
part of this amazing experience. 
 
 
